Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
Olumiant save search
Alumis Appoints Sapna Srivastava, Ph.D., to its Board of Directors
Published: 2022-08-03 (Crawled : 13:20) - biospace.com/
MS | News 0 d | $93.76 1.81% 0.12% 6.4M
|
Finance
|
| O: 1.38%
H: 1.07%
C: 0.44%
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
Published: 2022-06-14 (Crawled : 03:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.49%
H: 0.98%
C: 0.56%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -2.09%
H: 0.41%
C: -1.96%
olumiant fda
FDA Approves Lilly and Incyte's Olumiant For Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
covid-19 fda olumiant
FDA Approves Eli Lily's Olumiant For Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
covid-19 fda olumiant covid
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
Published: 2022-05-11 (Crawled : 11:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 2.48%
H: 1.15%
C: -2.43%
covid-19 olumiant treatment fda
Alumis Expands Industry-Leading Leadership Team With Appointments of Sara Klein as General Counsel and Secretary and John R. Schroer as Chief Financial Officer
Published: 2022-04-06 (Crawled : 12:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.99%
H: 0.0%
C: 0.0%
Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies
Published: 2022-03-26 (Crawled : 16:20) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
| Email alert
Add to watchlist
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
| Email alert
Add to watchlist
olumiant phase 3
Lilly’s Olumiant Portfolio Takes a Pair of Hits as Lupus Program Discontinued
Published: 2022-01-28 (Crawled : 19:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 3.25%
C: 3.2%
olumiant program air lupus
Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
Published: 2022-01-28 (Crawled : 14:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 3.25%
C: 3.2%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.2%
H: 3.93%
C: 3.89%
olumiant fda atopic dermatitis program dermatitis baricitinib phase 3 lupus
OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Published: 2021-09-30 (Crawled : 10:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 1.05%
H: 1.88%
C: -0.74%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.1%
H: 1.7%
C: 0.06%
hair regrowth growth phase 3
OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses
Published: 2021-06-01 (Crawled : 00:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.3%
H: 0.96%
C: 0.06%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.02%
H: 0.6%
C: -0.74%
rheumatoid arthritis phase 3
OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses
Published: 2021-04-23 (Crawled : 17:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.01%
H: 1.12%
C: 0.9%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.5%
H: 1.3%
C: 1.16%
dermatitis phase 3 atopic dermatitis
Lilly and Incyte’s Olumiant Shows Mixed Results Against COVID-19
Published: 2021-04-08 (Crawled : 15:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.35%
H: 0.56%
C: -0.19%
covid results covid-19
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.